AAPL   323.75 (+0.13%)
MSFT   184.35 (-0.30%)
FB   229.75 (-1.28%)
NVDA   348.63 (-1.24%)
CGC   16.79 (+4.03%)
BABA   217.09 (+1.28%)
GE   7.24 (+2.69%)
F   6.13 (+3.73%)
GILD   73.94 (+0.93%)
DIS   121.59 (+2.39%)
NFLX   420.68 (-1.55%)
BAC   26.08 (+4.99%)
BA   167.43 (+9.21%)
AAPL   323.75 (+0.13%)
MSFT   184.35 (-0.30%)
FB   229.75 (-1.28%)
NVDA   348.63 (-1.24%)
CGC   16.79 (+4.03%)
BABA   217.09 (+1.28%)
GE   7.24 (+2.69%)
F   6.13 (+3.73%)
GILD   73.94 (+0.93%)
DIS   121.59 (+2.39%)
NFLX   420.68 (-1.55%)
BAC   26.08 (+4.99%)
BA   167.43 (+9.21%)
AAPL   323.75 (+0.13%)
MSFT   184.35 (-0.30%)
FB   229.75 (-1.28%)
NVDA   348.63 (-1.24%)
CGC   16.79 (+4.03%)
BABA   217.09 (+1.28%)
GE   7.24 (+2.69%)
F   6.13 (+3.73%)
GILD   73.94 (+0.93%)
DIS   121.59 (+2.39%)
NFLX   420.68 (-1.55%)
BAC   26.08 (+4.99%)
BA   167.43 (+9.21%)
AAPL   323.75 (+0.13%)
MSFT   184.35 (-0.30%)
FB   229.75 (-1.28%)
NVDA   348.63 (-1.24%)
CGC   16.79 (+4.03%)
BABA   217.09 (+1.28%)
GE   7.24 (+2.69%)
F   6.13 (+3.73%)
GILD   73.94 (+0.93%)
DIS   121.59 (+2.39%)
NFLX   420.68 (-1.55%)
BAC   26.08 (+4.99%)
BA   167.43 (+9.21%)
Log in

NASDAQ:VTVTvTv Therapeutics Stock Price, Forecast & News

$2.83
-0.06 (-2.08 %)
(As of 06/3/2020 12:01 PM ET)
Add
Compare
Today's Range
$2.77
Now: $2.83
$2.87
50-Day Range
$1.96
MA: $2.48
$3.19
52-Week Range
$1.23
Now: $2.83
$4.23
Volume792 shs
Average Volume439,302 shs
Market Capitalization$191.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.83
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Read More
vTv Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VTVT
CUSIPN/A
Phone336-841-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.76 million
Book Value($0.77) per share

Profitability

Net Income$-13,040,000.00
Net Margins-870.88%

Miscellaneous

Employees52
Market Cap$191.79 million
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive VTVT News and Ratings via Email

Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.

vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions

How has vTv Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VTVT stock has increased by 16.5% and is now trading at $2.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of vTv Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics.

When is vTv Therapeutics' next earnings date?

vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for vTv Therapeutics.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter. View vTv Therapeutics' earnings history.

What price target have analysts set for VTVT?

2 equities research analysts have issued 12 month target prices for vTv Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they anticipate vTv Therapeutics' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 147.3% from the stock's current price. View analysts' price targets for vTv Therapeutics.

Has vTv Therapeutics been receiving favorable news coverage?

Headlines about VTVT stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. vTv Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news aboutvTv Therapeutics.

Are investors shorting vTv Therapeutics?

vTv Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,690,000 shares, an increase of 10.5% from the April 30th total of 1,530,000 shares. Based on an average daily volume of 713,400 shares, the days-to-cover ratio is currently 2.4 days. Currently, 20.1% of the company's shares are sold short. View vTv Therapeutics' Current Options Chain.

Who are some of vTv Therapeutics' key competitors?

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Opko Health (OPK), Amarin (AMRN), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO) and Trevena (TRVN).

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the following people:
  • Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
  • Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
  • Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
  • Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
  • Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Frazier Management LLC (1.63%), Two Sigma Investments LP (0.41%), Two Sigma Advisers LP (0.06%), Spark Investment Management LLC (0.04%) and Wedbush Securities Inc. (0.02%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View institutional ownership trends for vTv Therapeutics.

Which major investors are buying vTv Therapeutics stock?

VTVT stock was bought by a variety of institutional investors in the last quarter, including Frazier Management LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Spark Investment Management LLC, and Wedbush Securities Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas, and Ronald O Perelman. View insider buying and selling activity for vTv Therapeutics.

How do I buy shares of vTv Therapeutics?

Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $2.83.

How big of a company is vTv Therapeutics?

vTv Therapeutics has a market capitalization of $191.79 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.

What is vTv Therapeutics' official website?

The official website for vTv Therapeutics is www.vtvtherapeutics.com.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.